Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis
- 1 May 2017
- journal article
- review article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 79, 4-16
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohnʼs DiseaseInflammatory Bowel Diseases, 2012
- Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®)BioDrugs, 2012
- Comparative Pharmacokinetics and Tolerability of Branded Etanercept (25 mg) and Its Biosimilar (25 mg): A Randomized, Open-Label, Single-Dose, Two-Sequence, Crossover Study in Healthy Korean Male VolunteersClinical Therapeutics, 2011
- Critical interpretation of Cochran's Q test depends on power and prior assumptions about heterogeneityResearch Synthesis Methods, 2010
- Th1/Th17 Immune Response Is Induced by Mesenteric Lymph Node Dendritic Cells in Crohn's DiseaseGastroenterology, 2009
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementJournal of Clinical Epidemiology, 2009
- Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPostgraduate Medical Journal, 2007
- Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel diseaseGastroenterology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996